Its precise mechanistic role in AF pathophysiology remains unclear

The gap

Evidence profile

Sourced from the future work and inline gaps of the source papers, classified as general, drawn from work published between 2024 and 2026, spanning 4 journals. Those papers have been cited 35 times in total.

Supporting evidence — 4 representative gaps

• SIRT Family: Biological Functions and Therapeutic Targets (2026) · MedComm · doi

  The results of the transgenic mouse studies reviewed here show that whole ‑body and tissue ‑specific Sirt1–7 manipulations are 36 of 48 MedComm, 2026 powerful tools for establishing causality. Global and conditional KOs reveal where the loss of a given isoform is sufficient to trigger or accelerate disease. OE models, in turn, show where increased activity can prevent or delay pathology. Within this framework, the most promising drug targets are SIRTs whose deletion promotes disease, while moderate OE or activation is protective. SIRT1, SIRT3, and SIRT6 meet these criteria in many systems. The loss of these isoforms worsens metabolic, cardiovas- cular, neurodegenerative, renal, and inflammatory phenotypes. Their OE often improves insulin sensitivity, preserves mitochon- drial function, reduces inflammation, and extends healthspan. SIRT1, SIRT3, and SIRT6 activators can mimic key protective effects observed in transgenic mice. This genetic–pharmacologic concordance strongly supports further drug development. For other isoforms, the reverse logic applies. When KO is benefi- cial and OE is harmful, inhibition or degradation is more attrac- tive. SIRT2, SIRT5, and SIRT7 provide such examples in specific contexts. Sirt 2 deletion can ameliorate colitis, allergic airway dis- ease, some neurodegenerative models, and certain c ‑Myc ‑driven tumors. Sirt5 loss sensitizes cells to SIRT5-dependent cancers. Sirt 7 deficiency restrains liver and hematologic malignancies in selected settings. Corresponding inhibitors and degraders now exist. However, transgenic data also show that these isoforms can be protective in other tissues or phases of disease. This argues for context ‑specific, rather than global, inhibition strategies. Transgenic mouse models have therefore been indispensable for SIRT biology. They define causal gene functions, pinpoint disease ‑relevant cell types, validate targets in vivo, and allow for the testing of delivery and combination strategies. Moreover, they have important limitations. Mouse SIRT networks and disease trajectories are not identical to those in humans. Disease models are induced rather than spontaneous and do not fully recapitulate the natural course. Small ‑molecule modulators in mice are usually given systemically and lack the cell ‑type precision of genetic tools. Taken together, these points suggest clear priorities for the next generation of models, including for SIRT1, SIRT3, and SIRT6. First, models should favor inducible, adult ‑onset, cell ‑type ‑specific OE at defined expression levels. Second, they should include catalytic ‑dead and separation ‑of ‑function knock ‑ins that dissect individual domains or substrates. Third, combinatorial or double-allele strategies in disease-relevant genetic backgrounds are important. In parallel, tissue ‑targeted delivery systems, systematic mapping of SIRT ‒SIRT interactions, exploration in new disease areas and robust isoform ‑specific biomarkers are needed. Together, these tools are essential for converting current qualitative genetic insights into quantitative guidance for SIRT-directed drug discovery and clinical translation.

  generalfuture work
  Keywords: sirt disease models specific transgenic genetic mouse show tools loss drug protective isoforms strategies cell
• Association between systemic inflammation response index and atrial fibrillation in chronic obstructive pulmonary disease: a multicenter cross-sectional study (2025) · Frontiers in Medicine · cited 3× · doi

  Its precise mechanistic role in AF pathophysiology remains unclear. Future basic and clinical studies are warranted to further elucidate the specific molecular pathways, inflammation–immune interactions, and potential therapeutic targets involved in SIRI- mediated AF pathogenesis. Therefore, future well-designed prospective cohort studies and interventional clinical trials are warranted to clarify the temporal and causal relationship between SIRI and AF, as well as the underlying biological mechanisms.

  generalinline gaps
  Keywords: future clinical warranted siri well precise mechanistic role pathophysiology remains unclear basic further elucidate speci
• Metabolic mechanisms orchestrated by Sirtuin family to modulate inflammatory responses (2024) · Frontiers in Immunology · cited 28× · doi

  In this review, we summarize the crucial roles of SIRTs, as epigenetic regulators, play crucial roles in modulating cell metabolism and inflammation as epigenetic regulators. SIRTs exert their anti-inflammatory effects through diverse metabolic pathways. In general, SIRTs regulate glucose, lipid, and amino acid metabolism to finely tune inflammatory responses. The involvement of SIRTs in inflammation is primarily associated with epigenetic modifications, which are closely linked to intracellular NAD+ levels. These multifunctional protein PTMs contribute extensively to metabolic and inflammatory signaling pathways. Although numerous acetylated proteins regulated by SIRTs have been reported to date, other lysine acylation m o d i fi c a t i o n s , s u c h a s l a c t y l a t i o n , g l u t a r y l a t i o n , 2 - hydroxyisobutyrylation, and benzoylation, have received limited attention, possibly due to their lower prevalence within inflammatory cells. Henceforth, it will be crucial to understand the precise molecular basis of these novel PTMs, to provide valuable

  generalfuture work
  Keywords: sirts ammatory crucial epigenetic roles regulators metabolism ammation metabolic pathways ptms review summarize play modulating
• SIRT3/6/7: promising therapeutic targets for pulmonary fibrosis (2025) · Frontiers in Cell and Developmental Biology · cited 4× · doi

  The sirtuin family is an important class of deacetylases that are widely involved in the regulation of cellular metabolism, stress response, aging, and various diseases. The sirtuin family, especially the subtypes SIRT1, SIRT3, SIRT6, and SIRT7, plays a key role in the study of IPF. These sirtuin subtypes exhibit significant antifibrotic effects by regulating oxidative stress, inflammatory response, apoptosis, EMT, and fibrosis- related signaling pathways. Although a large number of studies have revealed the potential protective effects of Sirtuins in pulmonary fibrosis, the precise regulation of Sirtuins activity to achieve the desired therapeutic effect remains an important challenge. Natural compounds, synthetic small molecules, and gene editing strategies provide potential therapeutic approaches for the treatment of pulmonary fibrosis. In particular, the specific activation or inhibition of SIRT3, SIRT6, and SIRT7 may open up new directions for the treatment of pulmonary fibrosis. This article reviews the role of SIRT3, SIRT6 and SIRT7 in lung fibrosis, which are relatively understudied in the Sirtuins family. It analyzes their mechanisms of action in detail and discusses therapeutic strategies targeting SIRT3, SIRT6 and SIRT7 and their related molecular pathways, providing useful clues for the future search for new IPF treatment targets and the development of new therapies. Future treatment strategies may no longer rely on the regulation of a single target, but rather through the combined intervention of multiple pathways to regulate multiple key mechanisms of lung fibrosis. In addition, further optimizing the safety, efficacy and precision of Sirtuins targeted therapies and exploring the specific mechanisms of action of different subtypes will provide more options and strategies for clinical treatment. In short, the Sirtuins family has shown great potential for the treatment of pulmonary fibrosis. As research progresses, our understanding of its mechanism will be further deepened in the future, which will promote Sirtuins as a new and effective treatment. Although there are still some challenges, by overcoming the limitations of existing research and promoting the clinical it will surely bring application of Sirtuins targeted therapy, new treatment hope to IPF patients. Combined with multi- target therapy and early diagnosis, Sirtuins targeted therapy is expected to become an effective weapon against pulmonary fibrosis.

  generalfuture work
  Keywords: sirt fibrosis sirtuins treatment pulmonary family strategies sirtuin regulation subtypes pathways potential therapeutic mechanisms future

Questions about this gap